Article Text

Download PDFPDF
Review: pioglitazone does not reduce risk of mortality or cardiovascular events in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with type 2 diabetes, does pioglitazone reduce cardiovascular events, other adverse events, and mortality or improve health related quality of life?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Endocrine ★★★★★★☆


Embedded ImageData sources:

Cochrane Library (issue 3, 2006), Medline, EMBASE/Excerpta Medica (to August 2006), Controlled Clinical Trials, and reference lists.

Embedded ImageStudy selection and assessment:

randomised controlled trials (RCTs) ⩾24 weeks in duration that evaluated pioglitazone in adults with type 2 diabetes. 22 RCTs (n = 12 466, mean age range 54–64 y) met the selection criteria: pioglitazone v placebo (4 RCTs) or another oral antidiabetic medication (13 RCTs), or pioglitazone combined with other oral medications or insulin v another combination of oral medications or insulin (7 RCTs). Assessment of methodological quality included randomisation method, allocation concealment, blinding, intention to treat analysis, and …

View Full Text


  • For correspondence: Dr B Richter, Universitaetsklinikum Duesseldorf, Duesseldorf, Germany. richterb{at}

  • Source of funding: no external funding.